Nomacopan - Akari Therapeutics
Alternative Names: Coversin; EV 576; long-acting PAS-nomacopan; PAS-coversin; PAS-nomacopan; rEV 576; rVA576Latest Information Update: 28 Mar 2025
At a glance
- Originator Evolutec
- Developer Akari Therapeutics; Evolutec; US Army Institute of Surgical Research
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Antivirals; Eye disorder therapies; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Haemolytic uraemic syndrome
- Phase I/II COVID-19 pneumonia; Keratoconjunctivitis
- Preclinical Asthma; Dry age-related macular degeneration; Haemorrhagic shock; Subarachnoid haemorrhage; Traumatic brain injuries
- Suspended Thrombotic microangiopathy
- No development reported Guillain-Barre syndrome; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Uveitis; Wet age-related macular degeneration
- Discontinued Autoimmune disorders; Bullous pemphigoid; Inflammation; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in United Kingdom (Intravitreous)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Uveitis in United Kingdom (Intravitreous)
- 19 Aug 2024 Nomacopan - Akari Therapeutics is available for licensing as of 19 Aug 2024. www.akaritx.com 9423868